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Several predictive models are currently being used for risk stratification and clinical decision-making in cardiovascu-
lar medicine and primary healthcare.1,2 Most models are based 
on the traditional cardiovascular risk factors (TRF), that is, 
age, sex, blood pressure, total cholesterol, high- density lipo-
protein cholesterol, and smoking status, and with the estimated 
10-year risk of either cardiovascular mortality or event rate as 
outcome. However, it is evident that the traditional risk fac-
tors do not adequately reflect all cardiovascular risk because 
the majority of individuals who experience a first time car-
diovascular event have adverse levels in <2 traditional risk 
factors and are misidentified as being at low risk.3 Both the 
successes and shortcomings of the traditional risk factors have 
stimulated research into identifying additional biomarkers, 
that is, biological signals, which can be used to improve on 
current cardiovascular disease risk models, or are indicators 
of progressive subclinical disease and, as such, would have 
utility in predicting cardiovascular event risk, improve on tra-
ditional predictive models, and lead to more accurate treat-
ment decisions. Blood-based biomarkers that can be easily 
integrated into patient management in the primary care set-
ting are particularly desirable. Of the <60 different proteins 
screened to date, only 3, C-reactive protein (CRP), N-terminal 
prohormone of brain natriuretic peptide, and cardiac troponin 
I, have been shown, in combination only, to add incremen-
tal value to TRF-based predictive models of first-time CVD.4 
However, their clinical utility in preventive cardiology has not 
been clearly established. CRP, like other acute phase proteins, 
such as fibrinogen, is widely recognized to be a marker of a 
general inflammatory state that contributes to cardiovascular 
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disease, but its role in a specific causal pathway has yet to 
be defined. The use of cardiac troponin I has revealed a high 
prognostic potential of low troponin concentrations, but their 
clinical value in risk prediction has not been established.5 On 
the other hand, elevated blood levels of N-terminal prohor-
mone of brain natriuretic peptide indicate that individuals 
already have cardiovascular disease, and yet do not, as indi-
vidual biomarkers, add any information beyond the TRFs in 
terms of unaccounted risk or new risk associated with unrec-
ognized events.
Assessment of the clinical utility of these and other novel 
biomarkers across populations is complicated by differences 
in study sample characteristics and, perhaps most importantly, 
by the definition of the outcome. Using a composite end point, 
such as ischemic stroke, myocardial infarction (MI), coronary 
ischemia requiring revascularization, heart failure, and cardio-
vascular death, may increase the power of the study to detect 
signal, but can result in a loss of information from biomarkers 
associated with specific disease pathogenesis.
To address these issues, we applied a high throughput, 
microfluidics immunoassay platform6 for discovery and veri-
fication of protein biomarkers associated with specific CVDs 
using study sera from the large population-based Tromsø Study 
in Norway.7 The Tromsø Study provides a unique opportunity 
combining these 2 activities because of a high participation 
rate, the comprehensiveness of the study’s clinical examination 
and metadata, and the relatively high incidence of adjudicated 
hard coronary heart disease events (myocardial infarction and 
sudden cardiovascular death). The Tromsø Study provides 
an unusual opportunity to compare differences in biomarker 
profiles between males and females without the confounding 
effects introduced by using a composite end point.
The objective of the present study is to identify blood-based 
protein markers that add significantly to the prediction of inci-
dent 10-year MI adjusted for traditional risk factors and to 
select a multivariable biomarker model that improves model 
fit, discrimination, and reclassification beyond that of the tra-
ditional risk factor model in nondiabetic men and women.
Methods and Materials
Study Population
Serum samples were drawn from a subset of participants in the 
fourth survey of the Tromsø Study (1994–1995). The Tromsø Study 
is a single-center prospective, population-based study with repeated 
health surveys of officially registered inhabitants in the municipality 
of Tromsø, Norway.7 Eligible for the present study were all women 
aged 50 to 74 years and men aged 55 to 74 years and 5% to 10% 
samples of other subjects aged 25 to 85 years with valid written con-
sent (n=7895). The Tromsø Study was approved by the regional com-
mittee for medical research ethics.
Cases and controls were drawn from the Tromsø cohort to form a 
traditional case–control study. Cases were defined as all participants 
with no previous MI, ischemic stroke, coronary artery bypass graft-
ing, percutaneous coronary intervention, or self-reported angina at 
baseline and who experienced a first-ever MI (n=419) within 10 years 
of follow-up. Controls (n=398) were randomly selected from the en-
tire group of participants completing 10-year follow-up without an 
event of interest and using the same inclusion criteria as for the cases. 
We excluded subjects with self-reported diabetes mellitus or who had 
nonfasting glucose level ≥200 mg/dL or HbA1c ≥6.5% at baseline (42 
cases and 8 controls).
End Point Assessment
Incident cardiovascular events and mortality among the participants 
were recorded from the date of enrollment in 1994–1995 through to 
the end of follow-up, 31 December 2005. Adjudication of hospital-
ized and out-of hospital events was performed by an independent 
end point committee based on data from hospital and out-of hospital 
journals, autopsy records, and death certificates. The Norwegian na-
tional 11-digit identification number allowed linkage to national and 
local diagnosis registries. Cases of incident MI were identified by 
linkage to the discharge diagnosis registry at the University Hospital 
of North Norway with search for ICD 9 codes 410 to 414, 798, and 
799 in the period 1994–1998 and thereafter ICD 10 codes I20–I25, 
R96, R98, and R99. University Hospital of North Norway is the only 
hospital in the area serving the Tromsø population. Modified WHO 
MONICA/MORGAM criteria for MI were used and included clinical 
symptoms and signs, findings in electrocardiograms, values of car-
diac biomarkers, and autopsy reports when applicable (http://www.
ktl.fi/publications/morgam/manual/followup/form22.htm). Linkage 
to the National Causes of Death Registry at Statistics Norway al-
lowed identification of fatal incident cases of MI that occurred as out-
of-hospital deaths, including deaths that occurred outside of Tromsø, 
as well as information on all-cause mortality. Information from the 
death certificates was used to collect relevant information of the event 
from additional sources, such as autopsy reports and records from 
nursing homes, ambulance services, and general practitioners. The 
Norwegian Registry of Vital Statistics provided information on emi-
gration and death.
Data From the Baseline Clinical Examination
Information about smoking habits, prevalent diabetes mellitus, an-
gina pectoris, previous MI, stroke, and use of antihypertensive and 
lipid-lowering drugs was collected from self-administered question-
naires. The baseline examination comprised 2 visits with an interval 
of 4 to 12 weeks. At each visit, standardized measurements of height 
and weight were taken, nonfasting blood samples were collected, and 
specially trained personnel recorded blood pressure with an automat-
ic device (Dinamap Vital Signs Monitor, Tampa, Fla). Three readings 
were recorded with 1-minute intervals, and the average of the final 
2 readings from each visit was used in the analyses. The nonfast-
ing blood samples were collected from an antecubital vein and serum 
prepared by centrifugation after 1 hour respite at room temperature. 
Serum total cholesterol and triglycerides were analyzed by enzymatic 
colorimetric methods with commercial kits (CHOD-PAP for total 
cholesterol and GPO-PAP for triglycerides; Boehringer-Mannheim). 
Serum high-density lipoprotein cholesterol was measured after the 
precipitation of lower-density lipoprotein with heparin and manga-
nese chloride. The average of the serum lipid values from the 2 visits 
was used in analyses. Plasma glucose was measured by a hexokinase 
method. HbA1c was measured by an immuno-turbidimetric method 
on a COBAS Mira Plus Chemistry Analyzer (Roche Diagnostics, 
Basel, Switzerland) with reagents from the same company. Blood 
analyses were performed by the Department of Clinical Chemistry, 
University Hospital North-Norway, Tromsø.
Candidate Protein Biomarker Selection
A literature search for proteins associated with cardiovascular disease 
generated a list of >900 potential biomarker candidates. Candidate 
proteins were prioritized according to their association with the 
pathophysiology of coronary heart disease and atherogenesis, includ-
ing lipid/sterol trafficking, endothelial activation, vascular remodel-
ing, foam cell development, plaque destabilization, inflammation/
infection, vascular tone and hypertension, thrombosis/fibrinolysis, 
platelet activation, and lipid oxidation. Of the 165 prioritized mark-
ers, availability of reagents—capture and detection antibodies and 
standard analyte—and successful development of assays further re-
duced the number of screening candidates to 59. Data analyses in-
cluded results from the 51 assays whose performance characteristics 
met internal quality standards (see Methods and Materials in the Data 
Supplement and Tables I and II in the Data Supplement).
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Assay Development and Data Production Runs
Serum processing, assay development, and assay production 
runs were performed at a single site with dedicated staff and 
equipment. Individual sandwich-format immunoassays were 
developed for data production on a research platform that 
integrates an automated assay plate processing system with 
the molecular counting technology of the Erenna™ System. 
This approach to biomarker discovery as well as the molecular 
counting technology detection technology has been described 
previously.6,8,9 The campaign approach to assay development 
and production is described in detail in the Data Supplement. 
Briefly, capture and detection antibodies and standard ana-
lytes for each target protein were acquired from commercial 
sources (Table I in the Data Supplement) and assay condi-
tions, such as serum dilution buffer, serum dilution factor, 
and concentrations of capture and detection antibodies, were 
optimized to generate a standard curve within the biological 
range for each assay. Only assay reagents and protocols that 
met minimum criteria for sensitivity, specificity, and dynamic 
range were used in the data production runs (see Methods and 
Materials in the Data Supplement).
Statistical Analysis
Data Preprocessing
All statistical analyses were performed using STATA version 
13.0 (Stata corporation, College station, TX, USA) or SAS 
software 9.4 (SAS Institute Inc., Cary, NC, USA). Skewed 
numeric variables were transformed (log10, square root) to 
approximate a normal distribution. Less than 5% of values 
were missing for all but 3 of 51 production assays, which all 
had <9% missing. Data were assumed to be missing at ran-
dom, and the ICE command in STATA was used to impute 20 
data sets. Rubin’s rule was used to combine the results for the 
imputed data sets.
Association of Individual Markers With MI
We used logistic regression models to assess the association 
between each protein and MI with and without sex interaction, 
alone and adjusted for the traditional risk factors, and the inter-
action terms age×sex and blood pressure×blood pressure medi-
cation. All risk factors were included as continuous variables in 
the models, except for the binary variables sex, smoking, and 
blood pressure medication. OR were reported per 1 standard 
Table 1. Baseline Characteristics.* The Tromsø Study
Characteristic
Women Men
Cases, n=169 Controls, n=244 P Value Cases, n=250 Controls, n=154 P Value
Age, y 65.6 (7.2) 59.6 (8.4) <0.001 63.3 (8.2) 59.3 (8.8) <0.001
Systolic blood pressure, mm Hg 151.3 (25.5) 137.1 (21.8) <0.001 146.4 (19.5) 139.3 (20.7) <0.001
Diastolic blood pressure, mm Hg 84.3 (12.8) 78.8 (12.2) <0.001 84.8 (11.4) 81.6 (11.6) 0.006
Smoking, n (%) 77 (45.6) 90 (36.9) 0.077 115 (46.0) 59 (38.3) 0.13
Blood pressure medication, n (%) 23 (13.6) 20 (8.2) 0.077 31 (12.5) 6 (3.9) 0.004
Total cholesterol, mmol/L 7.39 (1.37) 6.81 (1.16) <0.001 6.80 (1.13) 6.57 (1.15) 0.049
HDL C, mmol/L 1.61 (0.46) 1.68 (0.44) 0.12 1.35 (0.39) 1.43 (0.39) 0.065
Lipid medication, n (%) 4 (2.4) 2 (0.8) 0.20 3 (1.2) 3 (1.2) 0.55
HbA1c, % 5.48 (0.34) 5.40 (0.32) 0.012 5.42 (0.38) 5.35 (0.35) 0.075
BMI, kg/m2 26.4 (4.7) 25.5 (4.4) 0.048 26.6 (3.5) 25.7 (3.2) 0.007
Apolipoprotein B 100, μg/mL 16.9 (11.4–26.3) 13.6 (9.6–21.4) 0.012 18.3 (13.0–27.0) 14.6 (9.9–21.8) 0.002
ApoBApoA1 0.009 (0.006–0.017) 0.007 (0.005–0.012) 0.007 0.011 (0.008–0.018) 0.009 (0.005–0.015) <0.001
Complement C3, mg/mL 213.6 (167.4–275.7) 229.5 (176.7–294.8) 0.10 223.6 (165.4–280.8) 210.1 (165.6–264.3) 0.35
Complement C3B, μg/mL 2.76 (2.14–3.48) 2.92 (2.33–3.46) 0.093 2.75 (2.23–3.35) 2.58 (2.09–3.10) 0.18
Carboxypeptidase B2, μg/mL 27.3 (23.9- 31.0) 26.6 (23.4- 29.9) 0.46 26.8 (22.7- 31.9) 24.8 (21.8- 29.2) 0.030
C-reactive protein, ng/mL 81.2 (32.2–174.5) 46.7 (21.0–104.4) 0.027 84.8 (40.7–186.2) 56.0 (27.2–131.4) 0.84
IP-10, ng/mL 0.036 (0.029–0.049) 0.036 (0.028–0.047) 0.73 0.035 (0.028–0.047) 0.033 (0.027–0.041) 0.47
Heat shock protein 70, ng/mL 2.97 (2.06–5.34) 2.41 (1.84–3.76) 0.001 3.36 (2.33–5.65) 2.97 (2.21–4.20) 0.13
Kallikrein, plasma, μg/mL 29.1 (25.0–34.5) 30.0 (24.8–35.2) 0.25 26.7 (22.6–32.8) 28.8 (24.0–33.3) 0.16
Lipoprotein (a), ng/mL 160.2 (84.3–496.2) 135.2 (67.1–341.5) 0.034 150.6 (64.4–513.7) 101.1 (54.9–189.4) 0.002
Matrix metalloproteinase 3, ng/mL 7.4 (5.6- 9.8) 6.7 (5.2- 9.1) 0.18 12.1 (8.9- 17.2) 11.1 (8.6- 15.1) 0.022
Matrix metalloproteinase 8, ng/mL 11.5 (7.8–18.0) 9.0 (6.4–15.3) <0.001 14.8 (9.2–22.5) 11.6 (7.5–19.0) 0.007
Matrix metalloproteinase 9, ng/mL 406.2 (290.0–596.8) 355.8 (241.4–480.9) <0.001 487.9 (340.4–662.7) 382.9 (268.0–545.7) <0.001
Myeloperoxidase, ng/mL 53.0 (40.6–76.9) 47.1 (31.8–64.7) <0.001 60.8 (41.0–90.4) 54.7 (38.8–79.2) 0.23
Brain natriuretic peptide Pro NT, ng/mL 0.14 (0.09–0.27) 0.17 (0.10–0.31) 0.63 0.16 (0.09–0.31) 0.14 (0.09–0.22) 0.074
Thrombospondin 4, μg/mL 0.75 (0.53–1.19) 0.71 (0.47–1.09) 0.83 0.83 (0.60–1.29) 0.68 (0.44–0.90) 0.16
Tissue inhibitor metalloproteinase 4, ng/mL 5.09 (3.99–7.20) 4.65 (3.60–5.98) 0.010 4.34 (3.50–5.37) 3.78 (3.00–4.61) <0.001
Values are mean (standard deviation), median (interquartile range), or number (percentage).
*Serum concentrations shown for proteins with test for difference between cases and controls by Students t test.
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deviation change in the predictor, where the standard deviation 
was calculated from the distribution in the control group.
Marker Correlation
To explore marker interdependence, we calculated pairwise 
spearman correlation coefficients between all variables (bio-
markers and traditional risk factors). The resulting correlation 
matrix was plotted as a heat map.
Multivariable Logistic Regression Models to Predict 10-
Year Incidence of MI
Two multivariable models were fitted and compared with our 
benchmark model, Model 1, which comprised the TRFs only. 
Each of the Models 2 and 3 were finalized by stepwise selec-
tion of new markers that minimized the Bayesian Information 
Criterion. All markers significantly associated with MI after 
adjustment for TRFs were candidates for Model 2. All vari-
ables that were selected for Model 2 were entered in Model 
3. Candidates for the stepwise selection into Model 3 were 
the interaction terms (markers by sex) that were significant 
in a model that was adjusted for the TRFs. No marker by sex 
interaction term improved model 3 when the main effect of the 
marker was included in the model. However, after removing 
the main effect of the marker, a few markers by sex interaction 
terms improved model 3. This suggests that the marker effect 
was only present for one of the sexes. The sex for which the 
marker had an effect was indicated in the interaction term as 
(female or male) ×biomarker. False discovery rates (FDR)10 
were calculated from the P values from the variables included 
in model 2 and model 3. The FDR in model 2 were calcu-
lated based on all assessed protein main effects, n=52, and 
the FDR in model 3 was based on additional 52 tests because 
of the assessed tests of interaction with sex. Model fit was 
assessed by Bayesian Information Criteria, area under the 
receiving operating characteristic curve, and Net reclassifica-
tion improvement (NRI).11,12 Because the study design was 
enriched for cases, the intercept term of each model was cor-
rected such that the mean risk predicted by the model reflected 
incidence of MI in the cohort (8.4%). To calculate NRI, the 
thresholds for moderate and high risk were set at 10% and 
20%, respectively. Model calibration was tested with the Hos-
mer–Lemeshow test using 10 risk groups.
Results
Median (interquartile range) levels of all biomarkers in men 
and women are shown in Table III in the Data Supplement.
Twenty-four individual markers plus the APOB100 to 
APOA1 ratio (ApoBApoA1) showed a crude association 
with MI (P<0.05) in men and women combined (Table IVA 
Figure 1. Standardized odds ratios (ORs) 
for incident myocardial infarction (MI) in 10 
years of follow-up. ORs are of traditional 
risk factors and of 52 serum protein bio-
markers adjusted for age, sex, age×sex, 
systolic blood pressure (SBP), SBP×blood 
pressure medication, smoking status, total 
cholesterol (CHOL), HDL cholesterol (HDL) 
in women and men (black bars). Red aster-
isks indicate biomarkers with significant 
differences in ORs between women (red 
bars) and men (blue bars). ORs were esti-
mated by logistic regression and expressed 
per 1-SD increase of values in controls. The 
Tromsø Study.
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in the Data Supplement), and three additional markers were 
significant in the sex-specific models (Table IVB and IVC in 
the Data Supplement). After adjustment for TRFs, 17 vari-
ables were significantly associated with incident MI in men, 
women, or in both combined (Table 1 and Figure 1; Tables 
IVA–IVC in the Data Supplement). All significant ORs and P 
values in Table IVA–IVC in the Data Supplement are shown 
in bold.
As summarized in Table 2, 11 variables were significantly 
associated with MI in the multivariable adjusted analyses 
of men and women combined: apolipoprotein B (ApoB100, 
OR=1.21), the ApoBApoA1 (OR=1.26), carboxypeptidase 
B2 (OR=1.21), CRP(OR=1.18), heat shock 70kDa protein 1B 
(OR=1.20), plasma kallikrein (KLKB1, OR= 0.81), lipopro-
tein (a) (LPa, OR=1.26), matrix metalloproteinase 8 (MMP8, 
OR=1.25), matrix metalloproteinase 9 (MMP9, OR=1.30), 
myeloperoxidase (MPO, OR=1.17), and tissue inhibitor of 
metallopeptidase 4 (TIMP4, OR=1.22; Table 2; Table IVA in 
the Data Supplement).
Five biomarkers were significantly different between men 
and women (test for interaction P<0.05; Figure 1; Table IVa 
in the Data Supplement). Complement C3 and C3b, CXCL10, 
and N-terminal prohormone of brain natriuretic peptide were 
protective in women and not significant among men (Table 
IVA and IVB in the Data Supplement). Conversely, thrombo-
spondin-4 (THBS4) conferred significant risk in men but not 
in women.
As shown in Figure 2, a moderate to high degree of bio-
marker interdependence were observed for 18 pairs of bio-
markers with spearman correlations >0.5. Seven were in the 
range 0.50 to 59, 4 in the range 0.60 to 69 (CTSG with MMP8, 
MMP9 and MPO, and ICAM1 with VCAM1), 5 in the range 
0.70 to 0.79 (CD14 with VCAM1 and ICAM1, and the pairs 
of MMP8, MMP9, and MPO), and 2 in the range 0.80 to 0.90 
(CCL5 with THBS1 and APOB100 with ApoBApoA1). One 
correlation coefficient had a negative value <−0.50 (APOA1 
with ApoBApoA1, r =−0.501).
Figure 3 shows the AUC comparing the TRF-based model 
with the 2 selected multivariable risk prediction models (with 
and without interaction terms with sex) that were selected 
based on the Bayesian Information Criterion. Models 2 and 
3 increased the AUCs by 0.027 and 0.035, respectively (P 
values 0.002 and 0.0004). The protein markers selected by 
the stepwise procedure not including sex interaction terms 
(Model 2) were ApoBApoA1, KLKB1, MMP9, and LPa. 
Model 3 was expanded from Model 2 with the addition of 
CXCL10 in women and THBS4 in men only (the interac-
tion terms female×CXCL10 and male×THBS4). As shown 
in Table 3, both models improved net reclassification with 
NRI=8.5% (P=0.024) and NRI=14.2% (P=0.0002), resulting 
from a slightly higher net distribution of cases classified up 
than noncases classified down. Table 4 presents the ORs for 
the 2 models. All ORs are equal to or have improved slightly 
compared with the TRF-adjusted estimates presented in Table 
IV in the Data Supplement. In model 2, the FDRs for the 4 
selected proteins ranged between 0.021 and 0.0048. In model 
3, the total number of candidate variables doubled from 52 
to 104 because of the inclusion of interaction terms with sex. 
Consequently, the FDRs were increased showing the highest 
values for CXCL10 in females (FDR=0.18) and THBS4 in 
males (FDR=0.16). Model calibration analyses did not show 
any significant deviation between predicted and observed risk. 
The Hosmer–Lemeshow test P values in the 20 imputed data 
sets ranged from 0.52 to 0.76 for model 2 and 0.14 to 0.91 for 
model 3.
Discussion
We evaluated 51 novel blood-based proteins for predicting 
10 year risk of MI in a case–control study drawn from the 
population-based Tromsø Study. After adjustment for TRFs, 
Table 2. Significant Odds Ratios for MI in Multivariable Adjusted Models*. The Tromsø Study
Crude Age Adjusted Multivariable Adjusted†
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
APOB100 1.45 (1.25–1.68) <0.001 1.41 (1.21–1.65) <0.001 1.21 (1.01–1.44) 0.034
ApoBApoA1 1.53 (1.31–1.77) <0.001 1.49 (1.27–1.74) <0.001 1.26 (1.06–1.52) 0.011
CPB2 1.18 (1.02–1.37) 0.031 1.21 (1.03–1.42) 0.020 1.21 (1.02–1.43) 0.026
CRP 1.49 (1.28–1.72) <0.001 1.39 (1.19–1.62) <0.001 1.18 (1.00–1.39) 0.048
HSPA1B 1.36 (1.19–1.57) <0.001 1.29 (1.12–1.50) <0.001 1.20 (1.03–1.40) 0.020
KLKB1 0.83 (0.72–0.96) 0.012 0.86 (0.73–1.00) 0.055 0.81 (0.68–0.95) 0.012
LPa 1.22 (1.07–1.40) 0.003 1.23 (1.07–1.42) 0.004 1.26 (1.09–1.47) 0.003
MMP8 1.45 (1.26–1.68) <0.001 1.38 (1.19–1.62) <0.001 1.25 (1.05–1.47) 0.011
MMP9 1.53 (1.33–1.77) <0.001 1.46 (1.25–1.69) <0.001 1.30 (1.10–1.54) 0.002
MPO 1.36 (1.18–1.56) <0.001 1.26 (1.09–1.46) 0.002 1.17 (1.00–1.37) 0.045
TIMP4 1.27 (1.11–1.46) <0.001 1.17 (0.99–1.38) 0.063 1.22 (1.02–1.46) 0.026
APOB indicates apolipoprotein B; ApoBApoA1, APOB100 to APOA1 ratio; CI, confidence intervals; CPB2, carboxypeptidase B2; CRP, 
C-reactive protein; HDL, high-density lipoprotein; HSPA1B, heat shock 70kDa protein 1B; KLKB1, plasma kallikrein; LPa, lipoprotein (a); 
MMP8, matrix metalloproteinase 8; MMP9, matrix metalloproteinase 9; MPO, myeloperoxidase; OR, odds ratios; and TIMP4, tissue inhibitor 
of metallopeptidase 4.
*ORs per 1 standard deviation change of transformed concentrations calculated in control subjects.
†Adjusted for age, sex, age×sex, blood pressure, blood pressure×blood pressure medication, total cholesterol, HDL cholesterol, and daily 
smoking.
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17 biomarker variables significantly improved discrimination 
and model fit. The discrimination, model fit, and reclassifi-
cation were further improved by adding multiple biomark-
ers to the TRF-based model. A composite of ApoB/ApoA1, 
KLKB1, LPa, and MMP9 increased the AUC by 0.027 with 
an NRI of 9%, and a further inclusion of sex-specific terms of 
TBHS4 for men and CXCL10 for women increased the AUC 
by 0.035 and the NRI to 14%.
Surprisingly, KLKB1, the principal activating protease of 
the plasma kallikrein/kinin pathway, showed a strong protec-
tive and independent association with MI in men and women. 
KLKB1 was the only single protein that borderline signifi-
cantly improved the discrimination as determined by the AUC. 
Two other plasma kallikrein/kinin pathway proteins, Factor 
XII (F12) and kininogen, were neither positively nor nega-
tively associated with MI. The role of the plasma kallikrein/
kinin pathway in cardiovascular disease remains unclear. 
Several studies analyzed the relationship of F12 with vascular 
thrombosis and cardiovascular events,13,14 but only 1 study also 
evaluated KLKB1.15 The comparison of results is complicated 
by differing study designs, blood matrices, outcomes, and the 
use of different measures of the analytes, which include detec-
tion of activated enzymes or of inhibitor-bound complexes, 
and activity assays. The anti-KLKB1 antibody reagents used 
in the present study recognize both prekallikrein (inactive) 
and kallikrein (activated); whether the detected analyte is 
complexed with inhibitors is not known.
The protein markers MMP8, MMP9, and MPO were all signif-
icantly associated with MI. Their enzymatic activities have been 
localized histochemically in vulnerable plaque phenotypes16–18 
Figure 3. Receiver operator characteristics curves for incident 
first ever myocardial infarction in 10 years of follow-up. The 
Tromsø Study.
Figure 2. Spearman correlation matrix of traditional risk factors and 52 serum protein biomarkers. The Tromsø Study.
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and have been associated with first ever MI.4,19,20 However, in 
the stepwise selection procedure, MMP9 was the only that was 
selected. This reflects a high degree of interchangeability between 
these markers as showed in the correlation matrix (Figure 2). The 
high degree of interdependence may suggest a common tissue 
source or immune response to an atherogenic exposure.
Our results support previous findings regarding 
ApoBApoA14,21 and LPa.22 These biomarkers have been evalu-
ated in many populations, using standardized reagents and for-
mats which we could not adapt to the research platform used in 
the present study. As a consequence, the absolute mass levels 
measured for these analytes in this study are not necessarily 
comparable to those reported in other populations. We did select 
antibody reagents with desirable epitope specificities where 
possible. For example, although apolipoproteins A1 and B100 
blood levels are considered insensitive to fasting state, we used 
ApoB100-specific assay antibody reagents (R&D) for screen-
ing in this nonfasting population to avoid possible confounding 
by postprandial changes in ApoB48 levels. To measure LPa, we 
acquired reagents to quantify protein levels independently of 
the Kringle 4 domain repeat isoforms, using a commercially 
available set of antibodies directed to the apo(a) moiety.23
We found that higher CXCL10 levels protected against 
myocardial infarction in women. Chemokines are inflamma-
tory cytokines which cause directed migration of leukocytes 
into inflamed tissue, and increased levels have been found in 
atherosclerotic lesions.24 In a small cross-sectional study on 
49 patients with acute MI and 44 healthy controls, a com-
bination of 7 chemokines, among them CXCL10, markedly 
improved prediction of disease.25 Although the sex-specific 
associations between CXCL10 and first-ever MI have not pre-
viously been studied in prospective population-based studies, 
Table 3. Net Reclassification of Study Participants Who Did (MI=Yes) and Those Who Did Not (MI=No) 
Experience a Myocardial Infarction for Models 2 and 3. The Tromsø Study
Model 2 Model 3 Percent in Risk 
ClassRisk Class <10% 10–<20% ≥20% <10% 10–<20% ≥20%
MI=Yes
Model 1 <10% 104 26 6 97 27 12 32.5%
10–<20% 32 76 40 29 74 45 35.3%
≥20% 1 22 112 3 20 112 32.2%
Percent in Risk 
Class
32.7% 29.6% 37.7% 30.8% 28.9% 40.3%
NRI
YES
=0.048, P=0.09 NRI
YES
=0.080, P=0.0071
MI=No
Model 1 <10% 251 16 0 252 14 1 67.1%
10–<20% 36 49 12 43 43 11 24.4%
≥20% 0 10 24 1 9 24 8.5%
Percent in Risk 
Class
72.1% 18.8% 9.0% 74.4% 16.6% 9.0%
NRI
NO
=0.037, P=0.11 NRI
NO
=0.062, P=0.0062
NRI
overall
=0.085, P=0.024 NRI
overall
=0.142, P=0.0002
Model 1: Traditional risk factors only (TRFs). Model 2: TRFs+ApoBApoA+KLKB1+LPa+MMP9. Model 3: TRFs+ApoBApoA+KLKB1+LPa+MMP
9+Females×CXCL10+Males×THBS4.
ApoBApoA1 indicates APOB100 to APOA1 ratio; CXCL10, C-X-C motif chemokine 10; KLKB1, plasma kallikrein; LPa, lipoprotein (a); MI, 
myocardial infarction; MMP9, matrix metalloproteinase 9; NRI, Net reclassification improvement; THBS4, thrombospondin-4; and TIMP4, tissue 
inhibitor of metallopeptidase 4.
Table 4. Odds Ratios for Myocardial Infarction in 2 Models*. The Tromsø Study
Term
Model 2 Model 3
OR (95% CI) P Value FDR OR (95% CI) P Value FDR
ApoBApoA1 1.34 (1.10, 1.64) 0.0037 0.048 1.40 (1.14, 1.71) 0.0012 0.062
KLKB1 0.72 (0.60, 0.86) 0.0004 0.021 0.73 (0.61, 0.88) 0.0011 0.114
LPa 1.27 (1.09, 1.49) 0.0027 0.047 1.29 (1.10, 1.51) 0.0020 0.069
MMP9 1.31 (1.10, 1.55) 0.0018 0.047 1.30 (1.10, 1.54) 0.0023 0.060
Female* CXCL10 … … … 0.69 (0.52, 0.91) 0.0085 0.177
Male*THBS4 … … … 1.38 (1.08, 1.77) 0.0094 0.163
ApoBApoA1 indicates APOB100 to APOA1 ratio; CI, confidence intervals; CXCL10, C-X-C motif chemokine 10; FDR, false discovery 
rate; KLKB1, plasma kallikrein; LPa, lipoprotein (a); MMP9, matrix metalloproteinase 9; OR, odds ratios; and THBS4, thrombospondin-4.
*ORs per 1 standard deviation change of transformed concentrations calculated in control subjects. Adjusted for age, sex, age×sex, 
blood pressure, blood pressure×blood pressure medication, total cholesterol, HDL cholesterol, and daily smoking.
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the MONICA/KORA study showed no significant association 
in women and men combined, in agreement with our results.26
We are not aware of population-based studies showing the 
association between Thrombospondin 4 and cardiovascular 
disease. However, THBS4 is a matricellular protein expressed 
by endothelial and smooth muscle cells and may be important 
in regulation of vascular inflammation. Our finding supports 
the suggestion that the thrombospondin proteins and their 
single-nucleotide polymorphisms play a significant role in 
cardiovascular pathology.27
Adjusted for the TRFs, CRP improved model fit in the total 
sample and in men, but not in women. The insignificant result 
in women is in agreement with the conclusion by the systematic 
review by Shah et al, in that CRP does not perform better than the 
Framingham risk equation.28 Their conclusion is also supported 
by our stepwise selection procedure that did not include CRP.
The variables included in our risk prediction models have 
all been linked to CHD but to some extent with conflicting res
ults.4,15,17,21,22,24,27 Our study is the first to demonstrate multi-
variable prediction models, including these variables adjusted 
for TRFs. Furthermore, we have assessed 1 model with and 1 
without biomarker interaction terms with sex, indicating a pos-
sible improved discrimination and reclassification by includ-
ing sex-specific biomarker terms. The NRI of 14% in model 3 
resulting from net 8% cases classified up and net 6% of non-
cases classified down indicate a highly relevant improvement 
compared with the TRF model. However, the robustness of our 
findings would be increased by replication in an independent 
cohort. The amount of reclassification presented here, which 
is dependent on calibration of the models, is likely to represent 
an upper bound in the number of cases and controls reshifted 
among risk categories that can be expected in an indepen-
dent cohort. Additionally, we cannot rule out the possibility 
of spurious associations because of sampling or experimental 
bias. The use of Bayesian Information Criterion as criterion 
in our selection process is equivalent with using a likelihood 
ratio test with P value threshold 0.01 (when the sample size 
is n=817). A 1% threshold implies an expected false-positive 
finding of <1 biomarker (out of 52) in model 2 and ≈1 false-
positive in model 3 (out of 104 possible terms in the regres-
sion model). However, the observed FDR was <0.047 for all 4 
included proteins in model 2, indicating the expected number 
of false positives to be 4×0.047=0.19. In model 3, the highest 
FDR of the 6 included proteins was 0.177, which indicate 1 
false-positive (6×0.177=1.06).
The high attendance rate, adjudication of events from 
records of the only local hospital, and negligible loss of partic-
ipants to follow-up are strengths of this study, as are the single 
site sample collection with standardized clinical exams and 
laboratory analyses, storage and documentation, and a high 
number of events. The use of frozen serum samples represent 
a limitation because it can have influenced the biomarker lev-
els and thereby the absolute risk estimates. Furthermore, the 
Tromsø population is a relatively homogenous middle-aged 
white population, and the results may not be applicable to 
other ethnic or age groups.
Conclusions
Ten-year risk estimation of MI was improved by adding novel 
protein biomarkers to the traditional risk factor model. The net 
reclassification was improved by 9% by adding ApoBApoA1, 
KLKB1, LPa, and MMP9 to the risk score model and further 
improved to 14% by including sex-specific terms of TBHS4 
for men and CXCL10 for women.
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CLINICAL PERSPECTIVE
Several predictive models are currently being used to estimate 10-year risk of either cardiovascular morbidity or mortality. 
Most models are based on traditional cardiovascular risk factors. However, it is evident that the traditional risk factors do 
not adequately reflect all cardiovascular risk as the majority of individuals who experience a first time cardiovascular event 
have adverse levels in <2 traditional risk factors and are misidentified as being at low risk. We aimed to survey 51 blood-
based protein markers to improve on traditional predictive models, which may lead to more accurate treatment decisions 
and add significantly to the prediction of incident 10-year myocardial infarction. Data in nondiabetic men and women from 
the Tromsø Study identified 2 models that improved 10-year prediction of MI beyond that of the traditional risk factors. The 
combination of apolipoprotein B/A1, kallikrein, matrix metalloproteinase 9, and lipoprotein (a) improved net reclassification 
of 8.5% to either low, median, or high-risk group. The net reclassification improvement increased to 14.2% by adding sex-
specific terms of thrombospondin 4 for men and C-X-C motif chemokine 10 for women to the model.
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SUPPLEMENTAL MATERIAL 
 
Supplemental Methods 
Blood and sample processing 
The study serum samples underwent no more than three freeze/thaw cycles from time of receipt to protein data 
production. All sera were kept at 4º C between sample dilutions, and were otherwise stored at -80º C until assay 
production.   
 
Assay Development and Data Production Campaigns 
Assay Reagents 
Immunoassay components were obtained from commercial sources, including R&D Systems, Inc. (Minneapolis, 
USA), United States Biological (Swampscott, USA), Abcam, Inc. (Cambridge, USA), Hytest Ltd. (Turku, Finland), 
Academy Biomedical (Houston, USA), AbD Serotec (Raleigh, USA), Novus Biologicals (St. Charles, USA), 
Mabtech (Cincinnati, USA), Biodesign (Memphis, USA), EMD Calbiochem (Billerica, USA), Mercodia, AB 
(Uppsala, Sweden),  and Affinity BioReagents (Golden, USA). See Supplemental Table 1. Two human serum pools 
were used as controls for assay development and data production:  Pooled normal human serum (NHS) from VWR 
International, LLC (Radnor, USA), and a Tromsø Study Pool (TSP) created by combining aliquots from 10%-16% 
of the study samples.   
 
Assay Development 
Antibody concentration, diluents, blocking agents and washes were optimized for each biomarker using factorial 
analysis, evaluating parameters of signal-to-noise ratio, lower limit of detection, upper limit of detection, 
parallelism, recovery and specificity. Acceptable assay performance criteria required the standard curve be near 4-5 
log Event Photons at the lower limit of detection, and 6-7 log Event Photons at the upper limit of detection, with a 
minimum of 2 logs linear range. A sample spiked with analyte, titrated within the linear range was required to have 
a slope parallel to that of the standard curve, and 80-120% recovery of the analyte was required for acceptance. 
Variance between with-in plates replicates was required to be <20%. 
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To identify the appropriate dilution range for the samples for each biomarker, the Tromsø Study Pool was diluted in 
assay buffer with 5-fold serial dilutions (5- to 1.9x106- fold dilution range).  The dilution closest to the midpoint of 
the standard curve was selected for data production.  Once the MRD was identified, study serum samples were 
placed in an 8x12 array, diluted with assay specific buffers and then stored at -80°C until ready to add to the 
immunoassay plates.   
For over 90% of the immunoassays, the anti-biomarker detection antibody was directly conjugated with AlexaFluor 
647 carboxylic acid, succinimidyl ester from Life Technologies (Carlsbad, USA) and conjugates were purified by 
ultrafiltration with Micron YM-30 from Millipore Corporation (Billerica, USA). Where a detection antibody was not 
available in unlabeled form, a biotinylated anti-biomarker antibody and AlexaFluor 647-conjugated streptavidin 
from Life Technologies was used for detection. All immunoassays were performed in 384-well NUNC Maxisorp 
plates sealed with pierceable heat sealing tape. 
 
Biomarker immunoassays/data production 
Sandwich-format immunoassays were performed in a total volume of 10 µL/well. Plates were prepared by adding 10 
µL capture antibody in diluent to each well and incubating overnight at room temperature (RT). Wells were washed 
and blocked with 60 µL  of assay specific blocking agent for 2-h at RT.  
Analyte for each standard curve was serially diluted to eight levels in assay buffer. Controls included replicates of 
the NHS and the TSP diluted to the same concentration as study samples, and a negative control (dilution buffer 
only). Diluted samples, standards, and controls were added (10 µL/well) to the coated wells  and incubated 
overnight at RT.  
After washing wells, anti-biomarker antibody was diluted in the appropriate buffer and dispensed into each well (10 
µL/well) and incubated for 2-h at RT. For immunoassays using biotinylated anti-biomarker antibody, an additional 
step followed with a wash, and the addition of 10 µL/well AlexaFluor 647-conjugated streptavidin at 1 ng/ml in 
assay buffer, then incubated for 2-h at RT. Wells were then washed and the antibody-analyte complexes were 
released from wells by adding 20 µL/well of 4 M Urea, 10 mM Boric Acid, 0.15 M NaCl, 0.001% BSA, 0.02% Triton 
X-100. This solution was used directly for molecular counting - based quantification (Bioanalysis. 2011 
Oct;3(19):2233-51) . 
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Molecular Counting 
Detection of AlexaFluor 647-labeled antibodies was performed on the Errena™ System (Singulex, Inc., Alameda, 
CA), which aspirates liquid from each well through an interrogation space within a capillary flow cell. Laser light 
(639 nm) is directed into the interrogation space, and  the resulting emission from each labeled antibody (668 nm) is 
measured via a confocal microscope with a photon detector. The photon detector transmits an electronic pulse for 
each photon detected, and pulses are counted in 1-ms bins. Only binned pulses that exceeded a 6-SD threshold 
above background are counted, so photons emitted from individual dye molecules are distinguished from 
background. Binned pulses are summed over a 1-min interval or until 1000 pulses are detected and recorded as 
photons/minute. 
Only one biomarker was measured per plate. Each plate included three replicates of each sample and controls, and 
six replicates of an eight-point standard curve generated from dilutions of known quantities of the specific 
biomarker. The concentration of biomarker in each sample was determined by interpolation of the mean of the 
replicates from the standard curve.  Production assay data that met the following criteria were entered into the study 
database: >70% samples detected, >2 logs standard curve linear range, and <20% replicate coefficient of variance 
(CV) between with-in plate replicates  
 
Assay Performance Metrics and Power Estimates 
Inter-assay (interplate) and total CVs were calculated for each assay run using the pooled serum controls: the TSP 
and the NHS in campaign 1, and two replicates of TSP  in campaign 2.  See Supplemental Table 2. 
Power to detect an odds ratio of a given magnitude was estimated for each assay through simulation. A simulated 
population consisting of 100,000 measurements of a normally distributed variable was generated.  Outcomes were 
assigned to each observation such that the percentage of positive outcomes in the population matched the prior 
probability in Tromsø (3.3%), and such that higher values of the variable were associated with outcome with a 
specified odds ratio. For a given assay, the values of the variable were scaled to the same mean and SD as observed 
in the study, and Gaussian noise was added corresponding to the total CV for that assay.  Samples were then 
randomly drawn from this population with the same number of cases and controls as in the present study, and a 
logistic regression model of the outcome was fit in each sample.  A total of 1,000 samples was drawn for each odds 
ratio and each assay, and the power was estimated as the fraction of samples where the coefficient of the fit was 
 4 
 
significant (p<0.05). This was done over 100 odds ratios covering a range between 1 and 2.5, equally spaced on a 
logarithmic scale. The odds ratios corresponding to 50% and 95% power were then estimated for each assay from a 
spline fit of the resulting power vs. OR curves.  
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Supplemental Table 1. Biomarker Immunoassay Reagents and Vendors. The Tromsø Study 
Gene  
Symbol 
Protein  
Name 
Capture  
Vendor 
Capture  
Catalogue # 
Analyte Control  
Vendor 
Analyte 
Control 
Catalogue # 
Detection  
Vendor 
Detection  
Catalogue# 
ACE angiotensin I converting enzyme 
1 
R&D Systems AF929 R&D Systems 929-ZN-010 R&D Systems 841366 
ADIPOQ adiponectin R&D Systems MAB10651 R&D Systems 1065-AP-050 R&D Systems AF1065 
AGER advanced glycosylation end-
product receptor 
R&D Systems MAB11451 R&D Systems 1145-RG-050 R&D Systems AF1145 
AGT angiotensingen R&D Systems MAB3156 VWR 80050-234 R&D Systems AF3156 
AHSG alpha-2-HS-glycoprotein/Fetuin 
A 
R&D Systems MAB1184 R&D Systems 1184-P1-050 R&D Systems AF1184 
ANG angiogenin R&D Systems 840307 R&D Systems 840309 R&D Systems 840308 
APOA1 apolipoprotein A-I Abcam ab17278 Biodesign A95120H Abcam ab7613 
APOB apolipoprotein B  Mabtech 3715-3-1000 Biodesign A50220H Mabtech 3715-5-250 
APOB100 apolipoprotein B 100 R&D Systems MAB4124 Biodesign A50220H R&D Systems AF3260 
APOC3 Apolipoprotein C-III Academy 
Biomedical 
33A-G2b Academy 
Biomedical 
33P-UP202 Academy 
Biomedical 
33A-R1b 
BGLAP osteocalcin Hytest 4OC8-6F9 Novus 
Biologicals 
H00000632-
Q01 
Hytest 4OC8-3H8 
BSG CD147/EMMPRIN R&D Systems MAB972 R&D Systems 972-EMN-050 R&D Systems AF972 
C3 complement C3 USBio C7850-14 abD Serotec 2222-5704 USBio C7850-10A 
C3b complement C3b USBio C7850-14 abD Serotec 2222-5909 USBio C7850-10A 
CCL5 RANTES R&D Systems 840216 R&D Systems 840218 R&D Systems 840217 
CD14 CD14 R&D Systems MAB3833 R&D Systems 383-CD-
050/CF 
R&D Systems AB383 
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Gene  
Symbol 
Protein  
Name 
Capture  
Vendor 
Capture  
Catalogue # 
Analyte Control  
Vendor 
Analyte 
Control 
Catalogue # 
Detection  
Vendor 
Detection  
Catalogue# 
CD163 CD163 R&D Systems MAB1607 R&D Systems 1607-CD-050 R&D Systems AF1607 
CD40LG CD40 ligand Hytest 4CD40 Cell Sciences CRC800B Hytest 4CD40 
CHIT1 chitinase 1 (chitotriosidase) R&D Systems MAB3559 R&D Systems 3559-GH R&D Systems AF3559 
CPB2 carboxypeptidase B2 Hytest 4TA1-13D5 Hytest 8TA1 Hytest 4TA1-13H4 
CRP C-reactive protein USBio C7907-09 USBio C7907-26A USBio C7907-10 
CST3 cystatin C  Hytest 4CC1 Hytest 8CY5 Hytest PCC2 
CTSG Cathepsin G USBio N2257 Affinity 
BioReagents 
RP-77525 USBio C2097-52 
CXCL10 IP-10 R&D Systems MAB266 R&D Systems 266-IP-
050/CF 
R&D Systems AF266-na 
DCN decorin R&D Systems MAB1432  R&D Systems 143-DE-100  R&D Systems AF143 
DPP4 dipeptidyl-peptidase 4  R&D Systems MAB1180 R&D Systems 1180-SE  R&D Systems AF1180  
F12 coagulation factor XII USBio F0019-03  USBio F0019-15  USBio F0019-06  
FTH1 ferritin USBio F4015 USBio F4015-21  USBio F4015-17  
HP haptoglobin USBio H1820-05  USBio H1820-03  USBio H1820-06  
HSPA1B heat shock 70kDa protein 1B R&D Systems MAB1663 R&D Systems CUSTOM 02 R&D Systems AF1663 
ICAM1 intercellular adhesion molecule 1 R&D Systems MAB720  R&D Systems ADP4-050  R&D Systems AF720 
KLKB1 Plasma Kallikrein USBio P6200-50  EMD 
Calbiochem  
529583-1MG  USBio P6201  
KNG1 kininogen 1 USBio K1800  R&D Systems 1569-PI-010  R&D Systems AF1569  
LBP Lipopolysaccharide-binding 
protein 
USBio L2525-27  R&D Systems 870-LP-
025/CF  
R&D Systems AF870 
LPa Lipoprotein (a) Mercodia CT1280  Mercodia 20-2517  Mercodia C1356 
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Gene  
Symbol 
Protein  
Name 
Capture  
Vendor 
Capture  
Catalogue # 
Analyte Control  
Vendor 
Analyte 
Control 
Catalogue # 
Detection  
Vendor 
Detection  
Catalogue# 
MMP3 matrix metalloproteinase 3 R&D Systems 841043 R&D Systems 841045 R&D Systems 841044 
MMP8 matrix metalloproteinase 8 R&D Systems MAB908 R&D Systems 908-MP-010  R&D Systems AF908  
MMP9 matrix metalloproteinase 9 R&D Systems 841028 R&D Systems 841030 R&D Systems 841029 
MPO myeloperoxidase Abcam ab10164 R&D Systems 3174-MP  R&D Systems AF3174  
NTproBNP brain natriuretic peptide Pro NT Hytest 4NT1-15C4  Hytest 8NT1  Hytest 4NT1-
13G12 
PLAUR uPAR R&D Systems MAB807 R&D Systems 807-UK-
100/CF  
R&D Systems AF807  
REN prorenin R&D Systems MAB4090  R&D Systems 4090-AS-020  R&D Systems AF4090 
SERPINE1 plasminogen activator inhibitor R&D Systems AF4090 R&D Systems 1786-PI-010  R&D Systems AF1786  
SERPINF2 serpin peptidase inhibitor, clade F  R&D Systems MAB1470  R&D Systems 1470-PI-010  R&D Systems AF1470  
SHBG sex-hormone binding globulin  R&D Systems mab2656 USBio S1012-54  R&D Systems AF2656  
THBS1 thrombospondin 1 R&D Systems MAB3074 R&D Systems 3074-TH-050  Genetec GTX22962  
THBS4 thrombospondin 4 R&D Systems MAB2390 R&D Systems 2390-TH-050  R&D Systems AF2390  
TIMP1 tissue inhibitor of 
metallopeptidase  1 
R&D Systems MAB970  R&D Systems 840296 R&D Systems 840295 
TIMP4 tissue inhibitor of 
metallopeptidase  4 
R&D Systems MAB974  R&D Systems 974-TSF-010  R&D Systems AF974 
TNFRSF11B osteoprotegerin R&D Systems MAB8051  R&D Systems 805-OS-
100/CF  
R&D Systems AF805  
TNFRSF1B tumor necrosis factor receptor, 1B  R&D Systems MAB726  R&D Systems 726-R2-050  R&D Systems AF726  
VCAM1 vascular cell adhesion molecule 1 R&D Systems MAB809  R&D Systems ADP5 R&D Systems AF809  
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Supplemental Table 2. Performance characteristics of Biomarker Immunoassays. The Tromsø Study 
  COEFFICIENTS OF VARIATION (%)  minimum 
sOR 
ASSAY CAMPAIGN CONTROL TOTAL INTER-
ASSAY 
 detectable @ 
95% POWER 
ACE 1 HSP/TSP 47% 52%  1.76 
ADIPOQ 1 HSP/TSP 31% 27%  1.32 
AGER 2 TSP 8% 1%  1.22 
AGT 1 HSP/TSP 38% 21%  1.16 
AHSG 2 TSP 11% 4%  1.28 
ANG 2 TSP 11% 8%  1.28 
APOA1 2 TSP 10% 8%  1.28 
APOB100 2 TSP 24% 19%  1.32 
APOC3 2 TSP 6% 4%  1.28 
BGLAP 1 HSP/TSP 24% 24%  1.10 
BSG 1 HSP/TSP 9% 8%  1.33 
C3 2 TSP 17% 8%  1.21 
C3b 2 TSP 15% 12%  1.28 
CCL5 1 TSP 27% na  1.18 
CD14 1 HSP/TSP 18% 6%  1.18 
CD163 1 HSP/TSP 10% 6%  1.26 
CD40LG 2 TSP 25% 24%  1.35 
CHIT1 2 TSP 6% 5%  1.18 
CPB2 2 TSP 12% 9%  1.29 
CRP 2 TSP 9% 8%  1.29 
CST3 2 TSP 26% 16%  1.42 
CTSG 1 HSP/TSP 18% 9%  1.32 
CXCL10 2 TSP 10% 8%  1.32 
DCN 2 TSP 9% 8%  1.32 
DPP4 1 HSP/TSP 21% 22%  1.41 
F12 2 TSP 12% 10%  1.34 
FTH1 1 HSP/TSP 23% 24%  1.52 
HP 2 TSP 10% 8%  1.24 
HSPA1B 2 TSP 19% 13%  1.27 
ICAM1 1 HSP/TSP 21% 6%  1.39 
KLKB1 2 TSP 9% 8%  1.32 
KNG1 2 TSP 11% 9%  1.32 
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  COEFFICIENTS OF VARIATION (%)  minimum 
sOR 
ASSAY CAMPAIGN CONTROL TOTAL INTER-
ASSAY 
 detectable @ 
95% POWER 
LBP 2 TSP 4% 3%  1.10 
LPa 2 TSP 13% 12%  1.28 
MMP3 1 HSP/TSP 22% 22%  1.34 
MMP8 2 TSP 7% 5%  1.12 
MMP9 2 TSP 7% 5%  1.12 
MPO 2 TSP 10% 9%  1.14 
NTproBNP 2 TSP 13% 13%  1.20 
PLAUR 2 TSP 13% 9%  1.19 
REN 1 HSP/TSP 26% 24%  1.32 
SERPINE1 2 TSP 13% 8%  1.24 
SERPINF2 2 TSP 15% 12%  1.30 
SHBG 2 TSP 23% 15%  1.38 
THBS1 1 TSP 38% na  1.56 
THBS4 2 TSP 19% 15%  1.26 
TIMP1 1 HSP/TSP 24% 17%  1.32 
TIMP4 2 TSP 6% 4%  1.12 
TNFRSF11B 1 HSP/TSP 27% 20%  1.35 
TNFRSF1B 1 HSP/TSP 16% 12%  1.25 
VCAM1 1 HSP/TSP 27% 23%  1.37 
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Supplemental Table 3. Baseline characteristics in MI cases and controls by sex. The Tromsø Study 
  Women  Men 
Characteristic n Median (IQR)* n Median (IQR)* 
ACE (ng/ml) 400 806.64 (529.29-1120.1) 393 820.71 (542.22-1132.7) 
ADIPOQ (µg/ml) 411 6.45 (  4.14-  9.60) 399 3.81 (  2.53-  5.57) 
AGER (ng/ml) 397 0.41 (  0.30-  0.52) 392 0.35 (  0.26-  0.45) 
AGT (ng/ml) 413 590.77 (230.79-1557.6) 403 624.76 (231.71-1711.0) 
AHSG (µg/ml) 396 902.47 (750.07-1048.2) 391 888.72 (764.81-1049.0) 
ANG (ng/ml) 380 195.14 (160.71-234.93) 387 218.27 (176.53-256.85) 
APOA1 (µg/ml) 394 1730.8 (1285.8-2094.9) 390 1505.2 (1153.2-1836.9) 
APOB (µg/ml) 396 14.77 (  9.92- 23.37) 391 16.82 ( 11.96- 24.39) 
APOBAPOA1 (ng/ml) 393 0.008 ( 0.005- 0.014) 389 0.011 ( 0.007- 0.016) 
APOC3 (µg/ml) 382 242.43 (199.10-303.89) 376 235.49 (196.92-284.94) 
BGLAP (ng/ml) 412 5559.3 (4304.3-7682.6) 402 5388.2 (4192.0-7234.4) 
BSG (ng/ml) 410 45.34 ( 36.91- 53.82) 403 42.24 ( 35.76- 48.78) 
C3 (mg/ml) 366 223.66 (172.68-280.46) 372 217.10 (165.52-275.06) 
C3B (µg/ml) 394 2.85 (  2.25-  3.46) 392 2.70 (  2.19-  3.28) 
CCL5 (ng/ml) 413 102.41 ( 47.77-212.94) 403 86.37 ( 47.36-184.99) 
CD14 (ng/ml) 410 233.52 (185.51-309.58) 403 228.88 (182.45-294.98) 
CD163 (ng/ml) 413 89.66 ( 52.62-165.71) 404 84.54 ( 56.21-153.24) 
CD40LG (ng/ml) 395 11.24 (  7.99- 15.25) 392 11.35 (  8.19- 15.76) 
CHIT1 (ng/ml) 396 41.88 ( 27.08- 59.04) 391 42.94 ( 27.37- 61.00) 
CPB2 (µg/ml) 397 26.99 ( 23.49- 30.59) 392 26.09 ( 22.29- 30.69) 
CRP (ng/ml) 397 56.03 ( 23.84-137.66) 391 68.06 ( 33.94-157.81) 
CST3 (ng/ml) 396 567.21 (475.71-750.01) 390 591.36 (470.04-727.64) 
CTSG (ng/ml) 413 28.59 ( 17.76- 45.35) 402 35.15 ( 21.64- 53.55) 
CXCL10 (ng/ml) 396 0.04 (  0.03-  0.05) 389 0.03 (  0.03-  0.05) 
DCN (ng/ml) 397 12.78 ( 10.89- 15.00) 391 13.18 ( 11.41- 15.41) 
DPP4 (ng/ml) 410 984.98 (728.92-1192.0) 403 912.96 (734.70-1158.8) 
F12 (µg/ml) 396 23.39 ( 18.34- 30.11) 392 23.02 ( 17.64- 28.75) 
FTH1 (ng/ml) 411 122.48 ( 63.40-241.56) 403 208.40 (110.46-422.90) 
HP (µg/ml) 393 758.16 (532.90-1077.8) 392 677.68 (399.11-1056.7) 
HSPA1B (ng/ml) 396 2.60 (  1.91-  4.23) 391 3.16 (  2.29-  4.97) 
ICAM1 (ng/ml) 410 31.69 ( 24.70- 43.56) 403 33.12 ( 25.34- 44.09) 
KLKB1 (µg/ml) 394 29.63 ( 24.84- 34.90) 391 27.22 ( 23.05- 33.00) 
KNG1 (µg/ml) 394 83.23 ( 69.42- 99.48) 392 83.50 ( 68.32-102.85) 
LBP (ng/ml) 397 920.05 (744.96-1097.6) 392 976.19 (778.83-1163.0) 
Supplemental Table 3. Baseline characteristics in MI cases and controls by sex. (cont’d) 
11 
 
  Women  Men 
Characteristic n Median (IQR)* n Median (IQR)* 
LPa (ng/ml) 396 141.41 ( 71.77-377.27) 391 129.09 ( 60.38-377.99) 
MMP3 (ng/ml) 410 7.02 (  5.27-  9.24) 403 11.52 (  8.73- 16.36) 
MMP8 (ng/ml) 396 10.26 (  6.64- 16.11) 391 13.24 (  8.81- 21.06) 
MMP9 (ng/ml) 397 372.96 (260.67-521.62) 392 444.39 (315.32-615.68) 
MPO (ng/ml) 397 50.12 ( 34.02- 70.20) 392 58.62 ( 40.62- 85.97) 
NTPROBNP (ng/ml) 396 0.16 (  0.10-  0.29) 391 0.15 (  0.09-  0.26) 
PLAUR (ng/ml) 396 1.60 (  1.25-  2.09) 392 1.61 (  1.21-  2.18) 
REN (ng/ml) 412 0.44 (  0.28-  0.67) 403 0.58 (  0.37-  0.87) 
SERPINE1 (ng/ml) 394 36.43 ( 28.97- 44.40) 390 39.58 ( 31.11- 48.24) 
SERPINF2 (ng/ml) 396 2608.8 (1480.6-3902.7) 390 2431.1 (1663.3-3580.2) 
SHBG (ng/ml) 397 1820.9 (1300.8-2493.8) 392 1344.9 (1013.8-1849.5) 
THBS1 (µg/ml) 409 34.87 ( 19.69- 59.59) 399 33.99 ( 20.07- 55.60) 
THBS4 (ng/ml) 396 737.53 (490.61-1136.6) 392 755.08 (512.42-1161.3) 
TIMP1 (ng/ml) 413 55.54 ( 40.17- 73.81) 404 58.30 ( 41.85- 75.38) 
TIMP4 (ng/ml) 396 4.73 (  3.74-  6.18) 392 4.10 (  3.27-  5.18) 
TNFRSF11B (ng/ml) 413 43.73 ( 32.66- 55.71) 404 41.61 ( 31.22- 53.83) 
TNFRSF1B (ng/ml) 413 18.18 ( 14.08- 22.21) 403 18.25 ( 14.58- 22.50) 
VCAM1 (ng/ml) 410 118.73 ( 89.06-152.65) 403 125.32 ( 94.95-162.48) 
* Values are median (interquartile range) 
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Supplemental Table 4a. Odds ratios for MI*. The Tromsø Study 
 Crude  Sex and age adjusted  Multivariable adjusted† p-value 
for sex 
diff.‡  
Variable OR (95% CI) p-value  OR (95% CI) p-value  OR (95% CI) p-value 
AGE 1.80 (1.55-2.10) <0.001  1.87 (1.60-2.19) <0.001  2.15 (1.65-2.79) <0.001 0.14 
SEX 2.34 (1.77-3.10) <0.001  2.59 (1.92-3.48) <0.001  2.40 (1.73-3.32) <0.001 Na 
CHOL 1.29 (1.12-1.47) <0.001  1.32 (1.14-1.53) <0.001  1.32 (1.13-1.55) <0.001 0.60 
HDL-C 0.74 (0.65-0.85) <0.001  0.73 (0.63-0.85) <0.001  0.71 (0.61-0.83) <0.001 0.84 
SYSBP 1.64 (1.42-1.90) <0.001  1.44 (1.23-1.69) <0.001  1.45 (1.23-1.71) <0.001 0.61 
SMOKE 1.41 (1.07-1.87) 0.015  1.82 (1.33-2.47) <0.001  2.00 (1.45-2.77) <0.001 0.35 
ACE 1.03 (0.90-1.18) 0.65  1.03 (0.90-1.19) 0.65  1.03 (0.89-1.20) 0.70 0.052 
ADIPOQ 0.88 (0.76-1.01) 0.060  0.83 (0.71-0.98) 0.030  0.97 (0.80-1.16) 0.71 0.67 
AGER 0.87 (0.75-1.01) 0.059  0.99 (0.84-1.15) 0.85  1.05 (0.89-1.24) 0.59 0.10 
AGT 1.00 (0.88-1.14) 0.99  0.98 (0.85-1.13) 0.79  1.01 (0.87-1.16) 0.93 0.19 
AHSG 1.13 (0.98-1.30) 0.090  1.14 (0.98-1.32) 0.080  1.06 (0.90-1.24) 0.50 0.72 
ANG 1.19 (1.03-1.37) 0.017  1.08 (0.93-1.26) 0.33  1.01 (0.86-1.19) 0.86 0.48 
APOA1 0.78 (0.67-0.92) 0.002  0.78 (0.66-0.93) 0.005  0.87 (0.71-1.05) 0.14 0.86 
APOB 1.45 (1.25-1.68) <0.001  1.41 (1.21-1.65) <0.001  1.21 (1.01-1.44) 0.034 0.33 
APOBAPOA1 1.53 (1.31-1.77) <0.001  1.49 (1.27-1.74) <0.001  1.26 (1.06-1.52) 0.011 0.43 
APOC3 1.02 (0.88-1.17) 0.81  1.11 (0.95-1.29) 0.18  0.97 (0.81-1.16) 0.71 0.19 
BGLAP 1.06 (0.93-1.21) 0.39  1.08 (0.93-1.25) 0.31  1.06 (0.91-1.23) 0.48 0.49 
BSG 1.02 (0.89-1.17) 0.80  0.99 (0.85-1.15) 0.89  0.93 (0.79-1.09) 0.37 0.60 
C3 0.93 (0.81-1.08) 0.37  0.96 (0.82-1.12) 0.57  0.87 (0.74-1.03) 0.11 0.015 
C3B 0.92 (0.80-1.06) 0.26  0.97 (0.84-1.13) 0.70  0.90 (0.77-1.06) 0.20 0.009 
CCL5 0.89 (0.77-1.03) 0.12  0.93 (0.80-1.08) 0.36  0.87 (0.74-1.02) 0.091 0.39 
CD14 1.13 (0.98-1.30) 0.092  1.04 (0.89-1.20) 0.64  1.02 (0.87-1.19) 0.81 0.51 
CD163 1.13 (0.99-1.30) 0.079  1.08 (0.93-1.25) 0.31  1.01 (0.86-1.18) 0.95 0.92 
CD40LG 0.90 (0.78-1.04) 0.16  0.96 (0.82-1.12) 0.60  0.95 (0.81-1.11) 0.52 0.67 
CHIT1 1.11 (0.96-1.28) 0.18  1.02 (0.87-1.20) 0.77  1.01 (0.86-1.20) 0.88 0.72 
CPB2 1.18 (1.02-1.37) 0.031  1.21 (1.03-1.42) 0.020  1.21 (1.02-1.43) 0.026 0.12 
CRP 1.49 (1.28-1.72) <0.001  1.39 (1.19-1.62) <0.001  1.18 (1.00-1.39) 0.048 0.50 
CST3 1.28 (1.10-1.47) <0.001  1.20 (1.03-1.40) 0.018  1.14 (0.97-1.35) 0.11 0.51 
CTSG 1.10 (0.96-1.26) 0.16  1.04 (0.90-1.21) 0.56  0.96 (0.82-1.12) 0.60 0.32 
CXCL10 1.02 (0.88-1.18) 0.82  0.91 (0.77-1.07) 0.26  0.87 (0.73-1.05) 0.15 0.048 
DCN 1.24 (1.08-1.42) 0.003  1.16 (1.00-1.34) 0.057  1.14 (0.98-1.34) 0.093 0.43 
DPP4 0.98 (0.86-1.13) 0.79  1.00 (0.87-1.16) 0.97  0.99 (0.85-1.16) 0.92 0.70 
F12 0.96 (0.84-1.11) 0.58  1.00 (0.86-1.15) 0.95  0.97 (0.83-1.14) 0.72 0.52 
Supplemental Table 4a.  Odds ratios for MI  (cont’d) 
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 Crude  Sex and age adjusted  Multivariable adjusted† p-value 
for sex 
diff.‡  
Variable OR (95% CI) p-value  OR (95% CI) p-value  OR (95% CI) p-value 
FTH1 1.07 (0.93-1.24) 0.33  0.96 (0.82-1.13) 0.63  0.88 (0.74-1.04) 0.14 0.87 
HP 1.19 (1.04-1.37) 0.013  1.25 (1.08-1.45) 0.003  1.08 (0.92-1.28) 0.33 0.54 
HSPA1B 1.36 (1.19-1.57) <0.001  1.29 (1.12-1.50) <0.001  1.20 (1.03-1.40) 0.020 0.91 
ICAM1 1.16 (1.01-1.34) 0.035  1.06 (0.91-1.23) 0.47  0.95 (0.81-1.12) 0.57 0.87 
KLKB1 0.83 (0.72-0.96) 0.012  0.86 (0.73-1.00) 0.055  0.81 (0.68-0.95) 0.012 0.73 
KNG1 0.97 (0.84-1.13) 0.71  0.98 (0.84-1.14) 0.75  0.91 (0.77-1.07) 0.25 0.10 
LBP 1.43 (1.24-1.64) <0.001  1.30 (1.13-1.51) <0.001  1.16 (1.00-1.36) 0.054 0.76 
LPa 1.22 (1.07-1.40) 0.003  1.23 (1.07-1.42) 0.004  1.26 (1.09-1.47) 0.003 0.58 
MMP3 1.39 (1.21-1.59) <0.001  1.08 (0.93-1.27) 0.31  1.14 (0.96-1.34) 0.13 0.16 
MMP8 1.45 (1.26-1.68) <0.001  1.38 (1.19-1.62) <0.001  1.25 (1.05-1.47) 0.011 0.96 
MMP9 1.53 (1.33-1.77) <0.001  1.46 (1.25-1.69) <0.001  1.30 (1.10-1.54) 0.002 0.66 
MPO 1.36 (1.18-1.56) <0.001  1.26 (1.09-1.46) 0.002  1.17 (1.00-1.37) 0.045 0.20 
NTPROBNP 1.01 (0.88-1.15) 0.90  0.84 (0.72-0.97) 0.019  0.86 (0.73-1.00) 0.057 0.037 
PLAUR 1.15 (1.00-1.32) 0.054  1.10 (0.94-1.27) 0.23  0.99 (0.84-1.17) 0.93 0.33 
REN 1.15 (1.00-1.32) 0.045  1.05 (0.90-1.21) 0.54  1.03 (0.87-1.21) 0.76 0.86 
SERPINE1 1.18 (1.03-1.37) 0.021  1.19 (1.02-1.38) 0.029  1.10 (0.93-1.29) 0.27 0.46 
SERPINF2 0.93 (0.81-1.08) 0.35  0.94 (0.81-1.10) 0.45  0.94 (0.80-1.11) 0.46 0.32 
SHBG 0.85 (0.74-0.99) 0.035  0.81 (0.69-0.96) 0.015  0.89 (0.74-1.07) 0.22 0.61 
THBS1 0.91 (0.79-1.05) 0.21  0.94 (0.81-1.10) 0.46  0.88 (0.75-1.04) 0.14 0.84 
THBS4 1.21 (1.05-1.39) 0.007  1.16 (1.00-1.34) 0.052  1.13 (0.97-1.32) 0.13 0.013 
TIMP1 1.09 (0.95-1.25) 0.21  1.05 (0.91-1.22) 0.50  0.96 (0.82-1.12) 0.62 0.13 
TIMP4 1.27 (1.11-1.46) <0.001  1.17 (0.99-1.38) 0.063  1.22 (1.02-1.46) 0.026 0.18 
TNFRSF11B 1.17 (1.01-1.35) 0.035  1.01 (0.86-1.18) 0.94  0.94 (0.80-1.11) 0.47 0.91 
TNFRSF1B 1.20 (1.04-1.38) 0.012  1.12 (0.96-1.30) 0.15  0.99 (0.84-1.17) 0.89 0.74 
VCAM1 1.15 (1.00-1.32) 0.051  0.97 (0.84-1.12) 0.68  0.99 (0.85-1.16) 0.91 0.69 
OR, Odds Ratios; CI, Confidence Intervals. 
*OR's per 1 standard deviation change of transformed concentrations calculated in control subjects.  
†Adjusted for age, sex, age*sex, blood pressure, blood pressure*blood pressure medication, total cholesterol, HDL 
cholesterol and daily smoking. 
‡Test of interaction between sex and each independent variable in the multivariable adjusted model. 
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Supplemental Table 4b. Odds ratios for MI in men*. The Tromsø Study 
 Crude  Age adjusted  Multivariable adjusted† 
 OR (95% CI) p-value  OR (95% CI) p-value  OR (95% CI) p-value 
AGE 1.61 (1.30-1.99) <0.001  1.61 (1.30-1.99) <0.001  1.69 (1.33-2.14) <0.001 
SEX na   na   na  
CHOL 1.23 (1.01-1.51) 0.044  1.25 (1.01-1.54) 0.039  1.29 (1.03-1.61) 0.024 
HDL-C 0.82 (0.67-1.00) 0.047  0.74 (0.60-0.92) 0.006  0.72 (0.57-0.89) 0.003 
SYSBP 1.49 (1.20-1.86) <0.001  1.35 (1.07-1.69) 0.011  1.31 (1.03-1.66) 0.025 
SMOKE 1.37 (0.91-2.07) 0.13  1.64 (1.07-2.53) 0.024  1.71 (1.09-2.67) 0.019 
ACE 0.93 (0.77-1.12) 0.44  0.94 (0.77-1.14) 0.52  0.90 (0.73-1.11) 0.32 
ADIPOQ 1.02 (0.84-1.25) 0.84  0.88 (0.71-1.09) 0.26  1.02 (0.80-1.29) 0.87 
AGER 1.07 (0.85-1.35) 0.56  1.12 (0.88-1.42) 0.37  1.24 (0.95-1.61) 0.11 
AGT 0.93 (0.77-1.11) 0.42  0.92 (0.76-1.11) 0.37  0.91 (0.75-1.11) 0.34 
AHSG 1.09 (0.89-1.34) 0.40  1.12 (0.91-1.38) 0.29  1.04 (0.83-1.31) 0.72 
ANG 1.17 (0.95-1.44) 0.13  1.18 (0.95-1.46) 0.14  1.09 (0.87-1.36) 0.46 
APOA1 0.87 (0.70-1.10) 0.24  0.83 (0.66-1.05) 0.13  0.91 (0.69-1.19) 0.47 
APOB 1.57 (1.24-1.98) <0.001  1.54 (1.21-1.95) <0.001  1.33 (1.02-1.72) 0.034 
APOBAPOA1 1.58 (1.25-1.99) <0.001  1.58 (1.24-2.01) <0.001  1.35 (1.03-1.76) 0.027 
APOC3 1.10 (0.90-1.33) 0.37  1.22 (0.99-1.50) 0.062  1.10 (0.87-1.40) 0.41 
BGLAP 1.04 (0.86-1.26) 0.67  1.06 (0.87-1.29) 0.56  1.00 (0.82-1.23) 0.98 
BSG 1.06 (0.86-1.30) 0.61  1.02 (0.83-1.27) 0.82  0.99 (0.79-1.24) 0.95 
C3 1.12 (0.91-1.37) 0.28  1.15 (0.93-1.41) 0.20  1.07 (0.86-1.33) 0.56 
C3B 1.14 (0.94-1.38) 0.19  1.18 (0.97-1.44) 0.11  1.13 (0.91-1.40) 0.26 
CCL5 0.92 (0.75-1.14) 0.46  0.93 (0.75-1.15) 0.51  0.94 (0.75-1.17) 0.57 
CD14 1.14 (0.94-1.39) 0.17  1.03 (0.84-1.26) 0.76  0.98 (0.80-1.21) 0.85 
CD163 1.06 (0.87-1.28) 0.58  1.03 (0.84-1.26) 0.78  0.99 (0.80-1.23) 0.93 
CD40LG 0.90 (0.73-1.11) 0.32  0.94 (0.76-1.16) 0.57  0.92 (0.74-1.16) 0.49 
CHIT1 1.10 (0.88-1.38) 0.42  1.00 (0.78-1.27) 0.98  1.00 (0.78-1.28) 1.00 
CPB2 1.35 (1.07-1.69) 0.011  1.41 (1.11-1.79) 0.005  1.43 (1.11-1.84) 0.005 
CRP 1.55 (1.23-1.94) <0.001  1.51 (1.20-1.90) <0.001  1.30 (1.02-1.65) 0.035 
CST3 1.35 (1.08-1.69) 0.008  1.29 (1.03-1.61) 0.029  1.23 (0.97-1.57) 0.084 
CTSG 0.96 (0.79-1.17) 0.72  0.98 (0.80-1.20) 0.83  0.90 (0.73-1.12) 0.36 
CXCL10 1.11 (0.88-1.40) 0.39  1.00 (0.79-1.27) 0.98  1.03 (0.80-1.32) 0.82 
DCN 1.23 (1.00-1.51) 0.051  1.23 (0.99-1.52) 0.059  1.24 (0.99-1.54) 0.056 
DPP4 0.99 (0.82-1.19) 0.89  1.01 (0.84-1.23) 0.88  1.03 (0.85-1.26) 0.74 
F12 0.99 (0.81-1.23) 0.96  1.07 (0.86-1.33) 0.56  1.03 (0.82-1.29) 0.79 
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 Crude  Age adjusted  Multivariable adjusted† 
 OR (95% CI) p-value  OR (95% CI) p-value  OR (95% CI) p-value 
FTH1 0.88 (0.73-1.07) 0.20  0.94 (0.77-1.14) 0.51  0.90 (0.73-1.11) 0.31 
HP 1.31 (1.07-1.61) 0.009  1.32 (1.07-1.63) 0.008  1.18 (0.93-1.50) 0.17 
HSPA1B 1.28 (1.05-1.57) 0.017  1.30 (1.05-1.60) 0.016  1.21 (0.97-1.50) 0.090 
ICAM1 1.21 (0.99-1.48) 0.065  1.11 (0.90-1.37) 0.33  1.00 (0.80-1.25) 0.99 
KLKB1 0.86 (0.70-1.06) 0.16  0.86 (0.70-1.06) 0.16  0.83 (0.67-1.04) 0.10 
KNG1 1.07 (0.87-1.32) 0.54  1.10 (0.88-1.36) 0.40  1.05 (0.84-1.32) 0.66 
LBP 1.43 (1.16-1.77) 0.001  1.38 (1.11-1.71) 0.004  1.24 (0.99-1.55) 0.065 
LPa 1.36 (1.12-1.65) 0.002  1.30 (1.07-1.58) 0.009  1.32 (1.07-1.62) 0.009 
MMP3 1.20 (1.00-1.45) 0.048  1.14 (0.94-1.37) 0.18  1.24 (1.02-1.52) 0.033 
MMP8 1.37 (1.11-1.69) 0.004  1.42 (1.14-1.78) 0.002  1.28 (1.00-1.64) 0.047 
MMP9 1.52 (1.23-1.88) <0.001  1.55 (1.25-1.93) <0.001  1.42 (1.11-1.80) 0.004 
MPO 1.17 (0.96-1.44) 0.12  1.19 (0.97-1.46) 0.10  1.09 (0.87-1.37) 0.44 
NTPROBNP 1.18 (0.98-1.42) 0.085  1.01 (0.82-1.24) 0.94  1.01 (0.81-1.25) 0.96 
PLAUR 1.28 (1.03-1.59) 0.024  1.21 (0.97-1.51) 0.091  1.10 (0.86-1.41) 0.44 
REN 1.03 (0.84-1.25) 0.79  1.05 (0.85-1.28) 0.66  1.03 (0.83-1.28) 0.80 
SERPINE1 1.17 (0.95-1.44) 0.13  1.24 (1.00-1.55) 0.049  1.17 (0.94-1.47) 0.16 
SERPINF2 0.98 (0.81-1.19) 0.86  1.00 (0.82-1.22) 0.99  1.01 (0.82-1.25) 0.90 
SHBG 1.05 (0.85-1.30) 0.65  0.85 (0.67-1.08) 0.19  0.88 (0.68-1.14) 0.34 
THBS1 0.87 (0.70-1.08) 0.22  0.89 (0.72-1.12) 0.33  0.87 (0.69-1.10) 0.24 
THBS4 1.38 (1.11-1.70) 0.003  1.36 (1.10-1.68) 0.004  1.37 (1.10-1.72) 0.005 
TIMP1 0.96 (0.79-1.17) 0.71  0.92 (0.75-1.12) 0.41  0.85 (0.69-1.06) 0.14 
TIMP4 1.50 (1.22-1.86) <0.001  1.32 (1.05-1.65) 0.017  1.37 (1.07-1.74) 0.011 
TNFRSF11B 1.14 (0.92-1.40) 0.23  0.99 (0.79-1.24) 0.94  0.94 (0.75-1.19) 0.61 
TNFRSF1B 1.18 (0.95-1.46) 0.13  1.11 (0.89-1.38) 0.37  1.00 (0.79-1.27) 0.99 
VCAM1 1.14 (0.94-1.37) 0.18  1.02 (0.84-1.24) 0.82  1.03 (0.84-1.26) 0.78 
 OR, Odds Ratios; CI, Confidence Intervals. 
*OR's per 1 standard deviation change of transformed concentrations calculated in control subjects.  
†Adjusted for age, sex, age*sex, blood pressure, blood pressure*blood pressure medication, total cholesterol, HDL 
cholesterol and daily smoking. 
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Supplemental Table 4c. Odds ratios for MI in women*. The Tromsø Study 
 Crude  Age adjusted  Multivariable adjusted† 
 OR (95% CI) p-value  OR (95% CI) p-value  OR (95% CI) p-value 
AGE 2.24 (1.77-2.84) <0.001  2.24 (1.77-2.83) <0.001  2.14 (1.63-2.80) <0.001 
SEX na   na   Na  
CHOL 1.53 (1.26-1.86) <0.001  1.35 (1.09-1.66) 0.005  1.38 (1.11-1.72) 0.004 
HDL-C 0.84 (0.70-1.01) 0.060  0.74 (0.60-0.90) 0.003  0.73 (0.60-0.90) 0.003 
SYSBP 1.78 (1.45-2.18) <0.001  1.49 (1.20-1.86) <0.001  1.58 (1.26-2.00) <0.001 
SMOKE 1.43 (0.96-2.13) 0.078  2.06 (1.32-3.22) 0.002  2.35 (1.47-3.78) <0.001 
ACE 1.15 (0.94-1.40) 0.18  1.14 (0.92-1.40) 0.23  1.22 (0.98-1.53) 0.082 
ADIPOQ 1.02 (0.84-1.24) 0.86  0.80 (0.64-1.00) 0.054  0.91 (0.70-1.17) 0.46 
AGER 0.83 (0.69-1.00) 0.055  0.89 (0.72-1.09) 0.25  0.92 (0.74-1.14) 0.43 
AGT 1.07 (0.88-1.29) 0.52  1.06 (0.86-1.30) 0.60  1.13 (0.91-1.41) 0.27 
AHSG 1.18 (0.97-1.44) 0.10  1.15 (0.93-1.42) 0.21  1.10 (0.88-1.38) 0.40 
ANG 1.05 (0.86-1.28) 0.65  0.97 (0.78-1.20) 0.77  0.97 (0.77-1.23) 0.82 
APOA1 0.85 (0.69-1.04) 0.12  0.74 (0.58-0.93) 0.012  0.85 (0.66-1.11) 0.23 
APOB 1.33 (1.09-1.62) 0.004  1.34 (1.09-1.65) 0.006  1.11 (0.88-1.41) 0.37 
APOBAPOA1 1.37 (1.13-1.66) 0.002  1.44 (1.17-1.77) <0.001  1.18 (0.93-1.50) 0.18 
APOC3 1.00 (0.81-1.22) 0.96  0.98 (0.79-1.21) 0.84  0.85 (0.66-1.10) 0.21 
BGLAP 1.13 (0.93-1.37) 0.23  1.08 (0.88-1.33) 0.47  1.11 (0.89-1.39) 0.36 
BSG 1.09 (0.89-1.32) 0.40  0.94 (0.76-1.16) 0.57  0.88 (0.70-1.12) 0.30 
C3 0.83 (0.67-1.02) 0.083  0.79 (0.63-1.00) 0.045  0.69 (0.54-0.89) 0.004 
C3B 0.80 (0.66-0.98) 0.035  0.80 (0.64-0.99) 0.042  0.73 (0.57-0.93) 0.011 
CCL5 0.90 (0.74-1.11) 0.33  0.93 (0.75-1.16) 0.54  0.79 (0.62-1.01) 0.060 
CD14 1.13 (0.92-1.38) 0.23  1.06 (0.86-1.31) 0.59  1.07 (0.85-1.34) 0.55 
CD163 1.22 (1.01-1.49) 0.044  1.12 (0.90-1.38) 0.31  1.04 (0.82-1.31) 0.76 
CD40LG 0.87 (0.71-1.07) 0.18  0.99 (0.80-1.23) 0.95  0.98 (0.78-1.25) 0.89 
CHIT1 1.14 (0.94-1.39) 0.18  1.06 (0.86-1.30) 0.59  1.04 (0.83-1.29) 0.76 
CPB2 1.11 (0.91-1.37) 0.31  1.01 (0.81-1.26) 0.91  1.07 (0.84-1.35) 0.59 
CRP 1.38 (1.13-1.68) 0.002  1.29 (1.04-1.59) 0.020  1.13 (0.89-1.43) 0.32 
CST3 1.27 (1.04-1.54) 0.018  1.12 (0.91-1.38) 0.28  1.10 (0.88-1.39) 0.41 
CTSG 1.14 (0.93-1.39) 0.20  1.11 (0.90-1.36) 0.35  1.04 (0.83-1.30) 0.73 
CXCL10 1.00 (0.81-1.22) 0.97  0.82 (0.65-1.03) 0.095  0.74 (0.57-0.97) 0.028 
DCN 1.19 (0.98-1.45) 0.086  1.06 (0.85-1.32) 0.58  1.09 (0.86-1.37) 0.49 
DPP4 1.02 (0.84-1.25) 0.81  0.97 (0.78-1.21) 0.80  0.95 (0.75-1.21) 0.69 
F12 0.98 (0.80-1.18) 0.80  0.89 (0.72-1.10) 0.29  0.94 (0.75-1.18) 0.59 
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 Crude  Age adjusted  Multivariable adjusted† 
 OR (95% CI) p-value  OR (95% CI) p-value  OR (95% CI) p-value 
FTH1 1.06 (0.85-1.31) 0.62  0.95 (0.76-1.20) 0.69  0.85 (0.67-1.10) 0.21 
HP 1.19 (0.97-1.46) 0.092  1.17 (0.95-1.46) 0.15  1.02 (0.80-1.29) 0.90 
HSPA1B 1.34 (1.11-1.62) 0.002  1.27 (1.04-1.55) 0.019  1.21 (0.98-1.50) 0.079 
ICAM1 1.08 (0.88-1.31) 0.47  1.03 (0.83-1.28) 0.77  0.93 (0.74-1.17) 0.52 
KLKB1 0.88 (0.72-1.09) 0.25  0.85 (0.68-1.07) 0.17  0.77 (0.60-0.99) 0.044 
KNG1 0.90 (0.73-1.11) 0.32  0.84 (0.66-1.06) 0.13  0.79 (0.61-1.01) 0.060 
LBP 1.38 (1.13-1.67) 0.001  1.23 (1.00-1.51) 0.052  1.13 (0.90-1.42) 0.29 
LPa 1.18 (0.97-1.43) 0.095  1.19 (0.96-1.46) 0.11  1.21 (0.97-1.52) 0.093 
MMP3 1.13 (0.94-1.37) 0.20  1.01 (0.82-1.24) 0.93  1.02 (0.82-1.27) 0.85 
MMP8 1.37 (1.12-1.67) 0.002  1.32 (1.07-1.63) 0.011  1.22 (0.96-1.54) 0.098 
MMP9 1.40 (1.15-1.71) <0.001  1.34 (1.08-1.66) 0.007  1.24 (0.98-1.56) 0.069 
MPO 1.41 (1.16-1.71) <0.001  1.30 (1.07-1.60) 0.010  1.28 (1.03-1.60) 0.027 
NTPROBNP 0.87 (0.71-1.05) 0.15  0.71 (0.57-0.88) 0.002  0.72 (0.57-0.91) 0.006 
PLAUR 1.04 (0.86-1.27) 0.68  1.01 (0.82-1.24) 0.94  0.90 (0.71-1.13) 0.36 
REN 1.06 (0.88-1.29) 0.52  1.03 (0.84-1.26) 0.78  1.04 (0.84-1.30) 0.71 
SERPINE1 1.08 (0.89-1.32) 0.43  1.12 (0.91-1.39) 0.28  1.04 (0.83-1.31) 0.73 
SERPINF2 0.89 (0.72-1.10) 0.28  0.88 (0.71-1.10) 0.28  0.86 (0.67-1.10) 0.22 
SHBG 0.89 (0.72-1.08) 0.24  0.82 (0.66-1.02) 0.071  0.92 (0.72-1.18) 0.53 
THBS1 0.95 (0.78-1.17) 0.65  0.99 (0.80-1.23) 0.92  0.89 (0.70-1.14) 0.36 
THBS4 1.08 (0.89-1.32) 0.43  0.95 (0.76-1.19) 0.66  0.93 (0.73-1.18) 0.56 
TIMP1 1.19 (0.98-1.45) 0.085  1.23 (0.99-1.52) 0.057  1.09 (0.87-1.36) 0.47 
TIMP4 1.36 (1.12-1.66) 0.002  1.01 (0.81-1.27) 0.90  1.10 (0.86-1.42) 0.44 
TNFRSF11B 1.24 (1.01-1.52) 0.039  1.01 (0.81-1.27) 0.92  0.95 (0.74-1.21) 0.66 
TNFRSF1B 1.21 (0.99-1.47) 0.066  1.13 (0.92-1.40) 0.24  0.98 (0.77-1.24) 0.86 
VCAM1 1.07 (0.87-1.31) 0.52  0.92 (0.74-1.15) 0.48  0.96 (0.77-1.22) 0.76 
 OR, Odds Ratios; CI, Confidence Intervals. 
*OR's per 1 standard deviation change of transformed concentrations calculated in control subjects.  
†Adjusted for age, sex, age*sex, blood pressure, blood pressure*blood pressure medication, total cholesterol, HDL 
cholesterol and daily smoking. 
 
